BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 363
- Registration Number
- NCT00185198
Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 110
- Registration Number
- NCT00185341
FC Patch Comparator Study
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 422
- Registration Number
- NCT00185354
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00185315
Efficacy and Safety Oral Contraceptive Study
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1113
- Registration Number
- NCT00185484
Efficacy and Tolerability of Angeliq in Thai Women
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 55
- Registration Number
- NCT00185328
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-12-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 414
- Registration Number
- NCT00185393
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 28
- Registration Number
- NCT00185302
Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 165
- Registration Number
- NCT00185237
Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 365
- Registration Number
- NCT00185276
© Copyright 2024. All Rights Reserved by MedPath